<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086822</url>
  </required_header>
  <id_info>
    <org_study_id>YLTKL-Ia-1</org_study_id>
    <nct_id>NCT05086822</nct_id>
  </id_info>
  <brief_title>A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ia Study on Tolerability and Pharmacokinetics of Irinotecan Hydrochloride Liposome Alone in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, dose-escalation and expansion, single centre, phase Ia study . In this&#xD;
      study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride&#xD;
      liposome injection were studied in patients with advanced solid tumors, to determine the&#xD;
      dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride&#xD;
      liposome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2014</start_date>
  <completion_date type="Actual">August 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A dose-escalation（3+3 design） and expansion study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>Assessed from study inclusion to 30 days after last dose</time_frame>
    <description>Assessed by CTCAE 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>DLTs will be evaluated during 21-day period following the first dose of study treatment</time_frame>
    <description>Dose limiting toxicities for patients in the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal tolerated dose (MTD)</measure>
    <time_frame>after the last patient in each cohort up to 12 months</time_frame>
    <description>Maximum tolerated dose for patients in the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>maximum time on study 12 months</time_frame>
    <description>Objective response rate was based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>The maximum time in follow up was 12 months</time_frame>
    <description>Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>up to 120 hours after the first dose</time_frame>
    <description>Tmax of total irinotecan, free irinotecan and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>up to 120 hours after the first dose</time_frame>
    <description>Cmax of total irinotecan, free irinotecan and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve from time zero to time of last observed concentration (AUC0-t)</measure>
    <time_frame>up to 120 hours after the first dose</time_frame>
    <description>AUC0-t of total irinotecan, free irinotecan and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve from time zero to infinity (AUC0-inf)</measure>
    <time_frame>up to 120 hours after the first dose</time_frame>
    <description>AUC0-inf of total irinotecan, free irinotecan and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>up to 120 hours after the first dose</time_frame>
    <description>T1/2 of total irinotecan, free irinotecan and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of drug from plasma (CL)</measure>
    <time_frame>up to 120 hours after the first dose</time_frame>
    <description>CL of total irinotecan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vss)</measure>
    <time_frame>up to 120 hours after the first dose</time_frame>
    <description>Vss of total irinotecan</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group : Irinotecan liposome</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan liposome</intervention_name>
    <description>Irinotecan liposome</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed solid tumors documented as advanced or&#xD;
             metastatic disease;&#xD;
&#xD;
          2. Subjects must be considered relapsed or refractory to standard therapies, have been&#xD;
             intolerant to standard therapies, or have refused standard therapy;&#xD;
&#xD;
          3. ECOG: 0-1;&#xD;
&#xD;
          4. Adequate organ and bone marrow function;&#xD;
&#xD;
          5. sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with brain malignant tumor, lymphoma or other malignant hematologic diseases;&#xD;
&#xD;
          2. Active CNS metastasis;&#xD;
&#xD;
          3. Clinically significant GI disorders;&#xD;
&#xD;
          4. Significant cardiovascular disease;&#xD;
&#xD;
          5. Active infection or uncontrolled fever;&#xD;
&#xD;
          6. Pregnant or breast feeding patients;&#xD;
&#xD;
          7. Allergic to a drug ingredient or component;&#xD;
&#xD;
          8. The investigators determined that other conditions were inappropriate for&#xD;
             participation in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

